Terry, you light-minded thinker, this is a "singular" event
with dual-action effect. Insmed's NTM results will pave the way for dual approvals of CF and NTM. If this "singular" even were negative, then Insmed would be forced to only pusue approval for CF in the EU/Canadian market and figure out which direction to approval in the US. NTM results won't be negative or even remotely equivocal, so your little "binary" even comment stems from ignorance trying to sound smart, quite a binary conundrum you deal with!